Delving into the Latest Updates on Alprazolam with Synapse

Overview

Basic Info

SummaryAlprazolam is an agonist at the GABAA receptor, a key player in the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) pathway. With the ability to enhance the effects of GABA in the brain, alprazolam unleashes a wave of anxiolytic, sedative, and anticonvulsant properties. Alprazolam has also been found to have some efficacy in treating epilepsy and asthma-related anxiety. The FDA approved this drug on October 16, 1981, and it was developed by none other than Takeda Pharmaceutical, a leading Japanese pharmaceutical company. Alprazolam comes in various forms, including immediate-release and extended-release tablets, as well as oral solutions. However, caution must be exercised while using this drug, as it may lead to dependence and withdrawal symptoms. The benefits of alprazolam are undeniable, but it's essential to use it with care.

Drug Type

Small molecule drug

Synonyms

8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine, Alprazolcem, AP-1002

+ [19]

Target

DOCK5 x GABAA receptor

Action

inhibitors, agonists

Mechanism

DOCK5 inhibitors(dedicator of cytokinesis 5 inhibitors), GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

DyssomniasCatatoniaDepressive Disorder+ [8]

Inactive Indication

Mild asthmaPanic

Originator Organization

Takeda Pharmaceutical Co., Ltd.Upjohn Pharmaceuticals Ltd.

Active Organization

UCB Japan Co., Ltd.UCB Pharma SAUCB Biopharma SRL

+ [7]

Inactive Organization

Viatris, Inc.VIATRIS Pharmaceuticals Ltd.

Mylan Pharmaceuticals, Inc.

+ [4]

License Organization

Alexza Pharmaceuticals, Inc.

Lee's Pharmaceutical Holdings Ltd.

Engage Therapeutics, Inc.

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (16 Oct 1981),

Anxiety DisordersPanic Disorder

RegulationBreakthrough Therapy (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC17H13ClN4

InChIKeyVREFGVBLTWBCJP-UHFFFAOYSA-N

CAS Registry28981-97-7

A female in her 20s presented to the emergency department (ED) following ingestion of what the patient reported was alprazolam. Unresponsiveness and respiratory depression prompted 6 mg of intranasal naloxone administration by emergency medical services prior to arrival to the ED. Comprehensive toxicological testing of serum revealed the presence of cychlorphine. Additional substances found were bromazolam, carboxy-THC, acetaminophen, caffeine, citalopram, cotinine, naloxone, naproxen, nicotine, and trazodone and its metabolite.

DISCUSSION:

This rare case of clinical signs of opioid overdose with cychlorphine detected is the first to provide direct evidence linking a non-fatal overdose to cychlorphine exposure. A naloxone responsive opioid toxidrome is described with an opiate and fentanyl negative initial urine drug screen. Advanced analytical techniques were required to identify the presence of cychlorphine.

25 Sep 2026·CURRENT DRUG TARGETS

Identification of Potential Therapeutic Target Genes for Bipolar Disorder through Systematic Druggable Genome-wide Mendelian Randomization

Article

Author: Ma, Cai-Yi ; Xiang, Chang-Cheng ; Jin, Yan-Ting ; Huang, Cheng-Bing ; Zhang, Tian-Yu

Introduction::

Bipolar Disorder (BD) is a severe psychiatric condition with high heritability and clinical heterogeneity. Despite numerous genetic variants linked to BD through Genome- Wide Association Studies (GWAS), the molecular mechanisms and effective therapeutic targets remain unclear. This study aims to identify potential therapeutic targets for BD using a systematic approach.

Methods::

In this study, we performed a systematic druggable genome-wide Mendelian Randomization (MR) analysis to identify potential therapeutic target genes for BD. We integrated large-scale GWAS data, expression Quantitative Trait Loci (eQTL) datasets, and druggable gene resources to construct a set of 6,888 potential druggable genes. MR methods were applied to infer causal relationships between these genes and BD. Additionally, Protein-Protein Interaction (PPI) network analysis, Gene Ontology (GO) enrichment analysis, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were conducted to explore the biological functions and pathways involved. Drug enrichment analysis was performed to assess the association between identified genes and approved psychiatric drugs, while Bayesian colocalization analysis was used to provide evidence for causal genetic signals underlying potential druggable targets.

Results::

Our MR analysis revealed 34 genes with significant causal associations with BD. These genes were found to be predominantly involved in immune regulation, neuro-metabolic processes, and oxidative stress-related pathways. Drug enrichment analysis identified a close association between these genes and several approved psychiatric drugs, including trifluoperazine, clozapine, and alprazolam. Further, Bayesian colocalization analysis provided strong evidence for GSTM1 and CD52 as potential druggable targets for BD, suggesting that their gene expression shares causal genetic signals with disease susceptibility.

Discussion::

Our findings support previous studies linking immune dysregulation to BD, with the identified genes enriched in immune-metabolic and oxidative stress pathways. A key limitation is the reliance on GWAS data primarily from European cohorts, which may limit the generalizability to other populations.

Conclusion::

This study prioritizes candidate druggable genes for BD through integrative analysis of GWAS, eQTL, MR, drug enrichment, and colocalization evidence. Our findings provide insights into BD-related molecular mechanisms and suggest potential avenues for target prioritization and drug repurposing research.

01 Sep 2026·EUROPEAN JOURNAL OF PHARMACOLOGY

An excitatory projection from ventromedial hypothalamus to lateral hypothalamus mediates stress-induced reinstatement of alprazolam-conditioned place preference in male mice

Article

Author: Tang, Susu ; Chen, Zhigang ; Hong, Hao ; Song, Zhipeng ; Song, Rui ; Li, Nianci ; Zheng, Cheng ; Long, Yan ; Yuan, Danhua ; Liao, Feizhi ; Wang, Cun

Alprazolam (Alp) is a clinically common benzodiazepine (BZD) with a potential risk of abuse, yet the mechanisms underlying its reinstatement remain unclear. In this study, a conditioned place preference (CPP) paradigm combined with forced swim stress (FSS) was employed to induce CPP reinstatement in male mice with prior Alp exposure. The results demonstrated that the activity of CaMKIIα neurons in the ventromedial hypothalamus (VMH) was significantly increased following FSS-induced reinstatement of Alp-CPP. The lateral hypothalamus (LH) receives innervation from the VMH, and GABAergic neurons in the LH were activated during this process. Chemogenetic inhibition of VMH^CaMKIIα-LH circuit significantly reduced FSS-induced reinstatement of Alp-CPP. Furthermore, chemogenetic activation of LH GABAergic neurons reversed the suppressive effects of inhibiting VMH CaMKIIα neurons projecting to the LH on Alp-CPP reinstatement. Collectively, these findings elucidate a critical role for the VMH^CaMKIIα-LH^GABA circuit in mediating stress-induced reinstatement of Alp-CPP in male mice, thereby advancing our understanding of the neural mechanisms underlying Alp reinstatement and providing novel insights for the prevention and treatment of BZD addiction.

97

News (Medical) associated with Alprazolam

24 Aug 2026

·www.sciencedaily.com

Common medications may change your gut for years

Common medications may reshape the gut microbiome long after the last dose is taken. In a study of more than 2,500 people, researchers found lasting microbial changes linked not only to antibiotics, but also to antidepressants, beta-blockers, acid-reducing drugs, and benzodiazepines. Some effects were still detectable years later, suggesting past medication use may strongly influence the gut bacteria people carry today.Medications can influence the community of microbes living in the human gut long after a person stops taking them, according to a large study led by researchers at the University of Tartu Institute of Genomics. The findings suggest that a person's prescription history may help explain differences in the gut microbiome years later. The gut microbiome includes the vast community of bacteria and other microorganisms that live in the digestive tract and can influence digestion, metabolism, immune function, and other aspects of health. Drug Effects May Persist for Years Researchers analyzed stool samples and prescription records from more than 2,500 participants in the Estonian Biobank who were part of the Estonian Microbiome cohort. They found that most of the medications examined were associated with differences in the gut microbiome. For a substantial number of drugs, those differences could still be detected years after people had stopped taking the medication. The lasting effects were not limited to antibiotics, which are already well known for their ability to disrupt populations of gut bacteria. Antidepressants, beta-blockers, proton pump inhibitors, and benzodiazepines were also associated with distinctive microbial "fingerprints." Beta-blockers are commonly used to treat conditions such as high blood pressure and certain heart problems. Proton pump inhibitors reduce stomach acid and are often prescribed for acid reflux and related conditions. Benzodiazepines are medications commonly used for anxiety and other disorders. "Most microbiome studies only consider current medications, but our results show that past drug use can be just as important as it is a surprisingly strong factor in explaining individual microbiome differences," said Dr. Oliver Aasmets, lead author. The finding suggests that researchers studying connections between the microbiome and disease may need to look beyond the medications a person is currently taking. Drugs used months or even years earlier could still influence the microbial patterns seen in a stool sample. Anxiety Drugs Show Surprisingly Strong Effects One particularly striking finding involved benzodiazepines, which are commonly prescribed for anxiety. Their associations with the gut microbiome were comparable to those seen with broad-spectrum antibiotics. Broad-spectrum antibiotics are designed to act against many different types of bacteria, which is why they can produce substantial changes in the gut microbial community. The study also found that medications belonging to the same drug class did not necessarily affect the microbiome in the same way. Drugs that may be prescribed for similar conditions, such as diazepam and alprazolam, differed in how strongly they appeared to disrupt gut microbes. That distinction could be important because medications are often grouped together in microbiome research based on their drug class. The new results suggest that individual drugs may need to be considered separately. Follow-Up Samples Reveal Predictable Changes Researchers also examined follow-up stool samples from a smaller group of participants. These samples allowed them to observe what happened when people started or stopped certain medications. Those changes were accompanied by predictable shifts in gut microbes, providing evidence that the medications themselves may be responsible for at least some of the observed differences. Although the second time-point analysis involved a relatively small number of participants, researchers were able to confirm persistent effects linked to proton pump inhibitors, selective serotonin reuptake inhibitors and antibiotics, such as penicillins in combination and macrolides. Selective serotonin reuptake inhibitors are a widely used class of antidepressants. Macrolides are a group of antibiotics that includes drugs used to treat a range of bacterial infections. Medication History Could Matter in Microbiome Research The results add to growing evidence that the gut microbiome reflects more than a person's current diet, lifestyle, health, and medication use. Past treatments may leave biological traces that remain detectable long after the prescription has ended. "This is a comprehensive systematic evaluation of long-term medication effects on the microbiome using real-world medical health records," said Professor Elin Org, corresponding author. "We hope this encourages researchers and clinicians to factor in medication history when interpreting microbiome data." Accounting for that history could help scientists more accurately distinguish microbiome changes associated with disease from changes caused by medications taken in the past.

Microbial therapy

30 Jun 2026

·www.einpresswire.com

Serenus Outpatient Detox Now Open in Jacksonville, FL, Offering Medically Supervised Outpatient Detox

A new medically supervised outpatient detox center opens in Jacksonville, giving Northeast Florida adults a clinical path to withdrawal care that fits life. Serenus Outpatient Detox provides safe, evidence-based outpatient detox services, letting clients receive the medical and clinical support needed while staying connected to family, work, and recovery.” — Donnie Huston, Executive Director at Serenus Outpatient Detox. JACKSONVILLE, FL, UNITED STATES, June 29, 2026 / EINPresswire.com / -- Serenus Outpatient Detox is now open in Jacksonville, Florida, bringing a new standard of medically supervised outpatient detox to Northeast Florida. Located at 11555 Central Pkwy, Suite 202, Jacksonville, FL 32224, the program provides structured, physician-overseen withdrawal care for adults seeking recovery from alcohol, opioids, benzodiazepines, stimulants, and other substances, without requiring an inpatient admission or residential stay. The program is open Monday through Friday, 7 AM to 7 PM; Saturday and Sunday, 8 AM to 2 PM, and is now accepting patients. Filling a Critical Gap in Jacksonville Drug & Alcohol Detox Serenus Outpatient Detox was founded by clinicians, counselors, and recovery advocates who identified a persistent gap in Northeast Florida's behavioral health landscape: people who needed safe, effective, medically supervised withdrawal care, but had work obligations, family responsibilities, or other circumstances that made inpatient detox impractical or simply not the right fit. Unlike residential treatment programs, Serenus provides medical detox in Jacksonville in an outpatient setting for individuals who need safe, evidence-based withdrawal care with daily medical monitoring, while continuing to live at home, work, and remain connected to their families, support systems, and everyday responsibilities. Clients visit the center daily for approximately two hours per visit. During each visit, nursing staff monitor vitals and manage withdrawal symptoms using FDA-approved medications tailored to each individual's history and medical needs. Clients also meet with a peer support specialist every day, receive weekly one-on-one sessions with a licensed substance use counselor, and participate in group programming centered on recovery, not just symptom management. Every detox protocol at Serenus is fully individualized. The clinical team builds each client's plan around their specific substance history, medical background, and recovery goals. A Full Range of Outpatient Detox Services The Jacksonville drug and alcohol detox program at Serenus treats withdrawal from a wide range of substances, including: - Alcohol, one of the most medically complex withdrawals and one the Serenus team is specifically equipped to manage safely - Opioids, including heroin, fentanyl, oxycodone, and hydrocodone - Benzodiazepines, including Xanax, Valium, Klonopin, and Ativan - Stimulants, including cocaine and methamphetamine - Prescription medications and other dependency-forming drugs Medication-assisted treatment options, including Vivitrol, are available on-site. The program also accommodates clients who are managing existing medication prescriptions from outside providers. From the first day of treatment, the Serenus team works alongside each client to develop a concrete aftercare plan, ensuring the right next step is identified and in place before the client completes the program. Serving Jacksonville & Northeast Florida Located in the Southside area of Jacksonville near Central Parkway, Serenus Outpatient Detox Jacksonville FL is accessible to individuals throughout Duval County and the broader Northeast Florida region, including Jacksonville Beach, Orange Park, Ponte Vedra, and surrounding communities. The program accepts most major insurance plans, and private-pay options are available. Serenus works closely with hospitals, primary care providers, therapists, non-profits, community partners, and behavioral health organizations throughout Northeast Florida. Providers and organizations interested in establishing a referral relationship are encouraged to reach out directly at 904-890-1442 or serenusdetox.com. For those seeking medical detox Jacksonville residents can rely on, Serenus offers a clinically rigorous, community-connected alternative to inpatient care. Grand Opening Open House: August 12 The Open House on August 12 will provide healthcare professionals, community partners, and members of the public an opportunity to tour the facility, meet the clinical team, and learn more about the medically supervised outpatient detox program at Serenus. Food and refreshments will also be provided. To RSVP for the August 12 open house, visit serenusdetox.com/open-house-rsvp. To learn more about outpatient detox Jacksonville FL services at Serenus, visit serenusdetox.com or call 904-890-1442. About Serenus Outpatient Detox is a medically supervised outpatient detox center located in Jacksonville, Florida. The program provides individualized, clinically comprehensive withdrawal care for adults seeking recovery from alcohol, opioids, benzodiazepines, stimulants, and other substances, without the need for inpatient admission. Serenus is built on the belief that safe detox and real recovery should fit inside your life. Donald Huston Serenus Outpatient Detox +1 904-890-1442 donnie@serenusdetox.com Visit us on social media: LinkedIn Instagram Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

15 May 2026

·www.mobihealthnews.com

OpenAI sued over alleged fatal ChatGPT drug advice

Editor's note: This article has been updated with a quote from OpenAI to MobiHealthNews. OpenAI is facing another lawsuit in California by parents alleging their son died from an accidental overdose after ChatGPT "coached him to mix Kratom and Xanax and provided an unprompted and lethal dosage recommendation." Tech Justice Law, Social Media Victims Law Center, and The Tech Accountability & Competition Project (housed at the Yale School of Law) filed the suit in San Francisco County Superior Court. The lawsuit against the tech giant was filed on behalf of Leila Turner-Scott and Angus Scott, parents of Samuel Nelson. Tech Justice Law Project claims Nelson had been receiving medical advice from ChatGPT for several months while the platform was "encouraging [him] to engage in increasingly dangerous behaviors." "Sam was also encouraged by ChatGPT to go to a dark, quiet room and was advised to take a deadly combination of a sedative (Benadryl) or benzodiazepines (Xanax) alongside a high dose of Kratom," the plaintiffs' attorneys allege. "ChatGPT failed to recognize the physical indicators that Sam was dying and did not recommend that he seek medical attention. Sam died from a fatal combination of alcohol, Xanax and Kratom." Tech Justice Law Project lawyers allege ChatGPT Health "distributed advice like a medical professional despite having no license, no training and no moral compass to do no harm" and that the platform could pose "serious risk" to consumers, claiming OpenAI is prioritizing speed over safety. OpenAI announced the release of ChatGPT Health earlier this year, which the company said combines an individual's personal health information with ChatGPT's intelligence. OpenAI said the platform aims to help people navigate the healthcare system and find answers to everyday health and wellness questions. Meetali Jain, executive director of the Tech Justice Law Project, stated in a release that OpenAI should be forced to pause its ChatGPT Health product until it is proven to be safe through rigorous scientific testing and independent oversight. "ChatGPT recommended a dangerous combination of drugs without offering even the most basic warning that the mix could be fatal. If a licensed doctor had done the same, the consequences under the law would be severe," Matthew P. Bergman, founding attorney of the Social Media Victims Law Center, said in a statement. In response to a request for comment, an OpenAI spokesperson told MobiHealthNews , "This is a heartbreaking situation, and our thoughts are with the family. These interactions took place on an earlier version of ChatGPT that is no longer available. ChatGPT is not a substitute for medical or mental healthcare, and we have continued to strengthen how it responds in sensitive and acute situations with input from mental health experts. The safeguards in ChatGPT today are designed to identify distress, safely handle harmful requests, and guide users to real-world help. This work is ongoing, and we continue to improve it in close consultation with clinicians."

100 Deals associated with Alprazolam

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00225	Alprazolam	N05BA12	DB00404

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Dyssomnias	South Korea	Unimed Pharmaceutical, Inc.	13 Mar 2025
Catatonia	Japan	Teva Takeda Pharma Ltd.	15 Feb 1984
Depressive Disorder	Japan	VIATRIS Pharmaceuticals Ltd.	15 Feb 1984
Depressive Disorder	Japan	Teva Takeda Pharma Ltd.	15 Feb 1984
Sleep Initiation and Maintenance Disorders	Japan	VIATRIS Pharmaceuticals Ltd.	15 Feb 1984
Sleep Initiation and Maintenance Disorders	Japan	Teva Takeda Pharma Ltd.	15 Feb 1984
Sleep Initiation and Maintenance Disorders	Japan	T’s Pharma Co., Ltd.	15 Feb 1984
Anxiety Disorders	United States	Upjohn US 2 LLC	16 Oct 1981
Panic Disorder	United States	Upjohn US 2 LLC	16 Oct 1981

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Epilepsy	Phase 3	Belgium	UCB SA	30 Jan 2022
Epilepsies, Myoclonic	Phase 3	United States	UCB Japan Co., Ltd.	10 Dec 2021
Epilepsies, Myoclonic	Phase 3	China	UCB Japan Co., Ltd.	10 Dec 2021
Epilepsies, Myoclonic	Phase 3	Japan	UCB Japan Co., Ltd.	10 Dec 2021
Epilepsies, Myoclonic	Phase 3	Australia	UCB Japan Co., Ltd.	10 Dec 2021
Epilepsies, Myoclonic	Phase 3	Bulgaria	UCB Japan Co., Ltd.	10 Dec 2021
Epilepsies, Myoclonic	Phase 3	Czechia	UCB Japan Co., Ltd.	10 Dec 2021
Epilepsies, Myoclonic	Phase 3	France	UCB Japan Co., Ltd.	10 Dec 2021
Epilepsies, Myoclonic	Phase 3	Germany	UCB Japan Co., Ltd.	10 Dec 2021
Epilepsies, Myoclonic	Phase 3	Hungary	UCB Japan Co., Ltd.	10 Dec 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04802746 (Pubmed \| Pulm Pharmacol Ther)	Phase 1	Mild asthma	83	Staccato alprazolam 1 mg (Healthy)	tbornakojq(ynotdxfkok) = plxpwncsrm avnimofihv (gdatxzhqjz ) View more	Positive	01 Jun 2026
				Staccato alprazolam 2 mg (Healthy)	tbornakojq(ynotdxfkok) = ecajeaazkl avnimofihv (gdatxzhqjz ) View more
NCT05626439 (P9-9.009, AAN2025)	Phase 1	Seizures	21	Staccato Alprazolam 2mg	crnwbzkgrf(nsdevosrpn) = nfbgjwvlzr dqaffoqvzw (iqtruvcokk )	Positive	07 Apr 2025
				Oral Alprazolam 2mg	crnwbzkgrf(nsdevosrpn) = lerjeyyhco dqaffoqvzw (iqtruvcokk )
NCT04782388 (UP0101, AAN2024)	Phase 1	-	-	Staccato Alprazolam 2 mg	alwczxnbwi(nmrigeigvl) = AUC0-t showed a similar trend to AUCinf wdvggiilzk (fbhylzrvfu ) View more	Positive	09 Apr 2024
				Staccato Placebo
NCT04970342 (PDID, CTgov)	Phase 1	-	13	Placebo (Lactose) Capsule+CBD+THC ("Sober" or Double Placebo)	bavzzwyhfo(ffqlcwegbt) = ecgtthmsvq uuhykznkvj (vlxobbglfx, 5.737) View more	-	25 Jul 2023
				CBD+0.75 mg Alprazolam Capsule+THC (Active Alprazolam (Xanax), Placebo Cannabis)	bavzzwyhfo(ffqlcwegbt) = lpfddbcpre uuhykznkvj (vlxobbglfx, 6.434) View more
NCT03478982 (ENGAGE-E-001, Pubmed)	Phase 2	Epilepsy	116	Staccato® alprazolam 1.0 mg	zxjufbvvth(pxrrytutku) = ugufnimbvp aqisimmxoo (mqsmpmvrfp )	-	21 Oct 2022
				Staccato® alprazolam 2.0 mg	zxjufbvvth(pxrrytutku) = uwahwuhqjz aqisimmxoo (mqsmpmvrfp )
NCT02351115 (CTgov)	Phase 2	Epilepsy	5	placebo (Inhaled Placebo)	jaklrkqzuu(fgtzvsrauz) = jmhxoweszp wetcqotjgs (yolemqvhxf, wzopcvnwyb - hbvxmervok) View more	-	10 Aug 2021
				Staccato+Alprazolam (Staccato Alprazolam, 0.5 mg)	jaklrkqzuu(fgtzvsrauz) = jcvcimttjf wetcqotjgs (yolemqvhxf, zrgmokrkal - rtcjdtbfpy) View more
NCT03478982 (StATES \| P1.5-023 \| ENGAGE-E-001, CTgov)	Phase 2	Seizures \| Epilepsy \| Epilepsies, Myoclonic	156	Staccato Alprazolam (STAP-001) (Open-label: Staccato Alprazolam (STAP-001) 1.0 Milligram (mg))	dfcfqiqaxg = mafktovbqx tjzxphihpu (ayygimcbrx, unsktwkpoe - mpvcyjxsyn) View more	-	03 Feb 2021
				placebo+alprazolam (Double-blind: Placebo)	dfcfqiqaxg = vtmhmgtcdm tjzxphihpu (ayygimcbrx, zslyhyxzcg - yolajhqojn) View more
NCT03297944 (CTgov)	Phase 4	Psychomotor Disorders	15	Placebo (PLC/PLC)+ZOL+PLC+Alprazolam+Zolpidem+ALC	omuwycurvr(ywmejzexps) = yuocivlzcs bjwknwfvjs (fssvwarukr, pdxbiyuklj - swdckubndl) View more	-	29 Jan 2020
NCT00603980 (CTgov)	Phase 1	Drug abuse	31	placebo (Placebo)	rrxruxfbbc(fsrmcqiufa) = uofqwgbcqr uqsnxqlnzs (ychhfhfcrf, 0.349) View more	-	02 Jan 2020
				Alprazolam (Oral Alprazolam 1 mg)	rrxruxfbbc(fsrmcqiufa) = pwueenbtcl uqsnxqlnzs (ychhfhfcrf, 0.349) View more
NCT00662259 (GAD, CTgov)	Phase 4	Generalized anxiety disorder	32	Xanax (Alprazolam)	vvyywhnlmq(twlhfxqshx) = blzaekwclp qylyjbblgn (vbgrxuuugh, .1529) View more	-	25 Jul 2019
				Placebo (Placebo)	vvyywhnlmq(twlhfxqshx) = mviunbkkyi qylyjbblgn (vbgrxuuugh, .1123) View more